Summary:
This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786, as compared with placebo, for the treatment of negative symptoms of schizophrenia.
Inclusion Criteria:
- Participants who meet the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-V) diagnostic criteria for schizophrenia confirmed by the Mini International Neuropsychiatric Interview (M.I.N.I) Version 7.0.2
- Participants must meet Positive and Negative Syndrome Scale (PANSS) criteria
- Participants currently receiving a second-generation atypical antipsychotic drug (SGA) are eligible provided they are on a stable dose
Exclusion Criteria:
- Participants with current major depressive disorder (MDD)
- Participants with pseudo-parkinsonism secondary to their ongoing antipsychotic medication
- Participants currently using anticholinergic medications
- Participants recently hospitalized as in-patients
Qualified Participants May Receive:
Monetary compensation and study-related care at no cost to the participant.